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Abstract
The aim of the present study is to investigate the influence of the environmental factors, smoking and alcohol, 
on the biotransformation of cyclophosphamide (CP) in the rat in vivo and in vitro with S9 liver fractions. The 
biotransformation of CP was studied by the determination of the CP metabolites, nor-nitrogen mustard (NNM), 
4-ketocyclophosphamide (KCP), and carboxyphosphamide (CAR). The effect of the environmental factors, smoking 
and alcohol consumption, on the biotransformation enzymes was mimicked by pretreatment of rats with 
ß-naphthoflavone and ethanol, respectively. Rats treated with olive oil and water served as controls and rats 
pretreated with Aroclor 1254 and phénobarbital were used as positive controls. The influence of sex and 
supplementation with NAD and GSH, mimicking a bioiogical variation in NAD and GSH levels in rat and human 
liver, was also studied. Pretreatment of rats with Aroclor 1254 decreased the excretion of unmetabolized CP in urine, 
most likely due to an enhanced biotransformation. The in vitro hepatic biotransformation of CP in rats was strongly 
influenced by sex, by supplementation with NAD and GSH, and by pretreatment with the enzyme-inducers, 
phénobarbital and Aroclor 1254. No influence of pretreatment with the enzyme-inducers, ß-naphthoflavone and 
ethanol, was found. The results suggest that the influence of the environmental factors, alcohol consumption and 
smoking, on the biotransformation of CP in man will be negligible.
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1. Introduction
Cyclophosphamide (CP) is an important anti- 
neoplastic drug used in the chemotherapy of 
cancer and autoimmune diseases. The activity of 
CP is caused by its metabolites (Sladek, 1988). 
During bioactivation by hepatic cytochrome
[42
P450, 4-hydroxycyclophosphamide is formed 
which is in equilibrium with its ring-opened 
tautomer aldophosphamide (Fig. 1). Both meta­
bolites are detoxified by isoenzymes of the NAD» 
linked aldehyde oxidase and aldehyde dehydro­
genase resulting in the formation of 4-ketocyc­
lophosphamide (KCP) and carboxyphosphamide
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Fig. 1. Abridged scheme of the biotransformation of CP showing only the currently recognized biologically important reactions 
and metabolites (after Sladek, 1988).
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(CAR), respectively. Toxification occurs after j3- 
elimination of acrolein from aldophosphamide to 
yield phosphoramide mustard which is further 
converted to nor-nitrogen mustard (NNM). 
Phosphoramide mustard is responsible for the 
DNA-alkylating activity resulting in the 
cytotoxic effect of CP. Acrolein binds covalently 
to proteins. M ost CP(metabolites) are ultimately 
eliminated by renal excretion.
In several recently published studies we have 
investigated the exposure of hospital workers to
CP (Sessink et al., 1992a,b; 1994a,b; 1995b). It
was found that during drug handling the workers 
were exposed to this compound. Despite the 
introduced guidelines and protective measures, 
we were able to detect CP in their urine. It was 
concluded that uptake of CP due to occupational 
exposure did happen. The question is to what 
extent the amounts of CP excreted in urine are a 
measure for the uptake of the drug. More precise­
ly, what is the relationship between uptake and 
urinary excretion of CP. Several processes such 
as the biotransformation, resulting in transform­
ation of the parent compound in metabolites, are 
involved. Differences in biotransformation are 
genetically determined but are also influenced by 
chemical exposure from the environment among 
which so-called life style factors, that may cause 
induction or inhibition of enzymes involved in 
the biotransformation of toxic compounds such 
as CP (Fournier and Thomas, 1986).
In the present study the in vitro biotransfor­
mation of CP was investigated using S9 liver 
fractions of pretreated and control rats. The 
biotransformation of CP was studied by the 
determination of the CP metabolites, nor-nitro­
gen mustard (NNM ), 4-ketyocyclophosphamide 
(KCP), and carboxyphosphamide (CAR). The 
effects of the environmental factors, smoking 
and alcohol, on biotransformation enzymes were 
mimicked by pretreatment of rats with jS-naph- 
thoflavone and ethanol, respectively (Pelkonen et 
al., 1986; Sesardic et al., 1987). The results were 
compared with the results obtained from control 
rats (olive oil and water pretreatment, respective­
ly) and from rats pretreated with Aroclor 1254 
and phénobarbital, respectively (positive con­
trols). The influence of sex and supplementation
with NAD and GSH, mimicking a biological 
variation in NAD and GSH levels in rat and 
human liver, was also studied. We were especially 
interested in the balance between toxication and 
detoxication which is expressed by the toxic/non­
toxic metabolites ratio NNM /(KCP-hCAR).
Several investigators have studied the in 
vitro hepatic biotransformation of CP in rats 
after pretreatment with phénobarbital, Aroclor 
1254, jS-naphtoflavone and 3-methylcholanthrene 
(Sladek, 1988; Clarke and Waxman, 1989; LeB- 
lanc and Waxman, 1989). In our study, we were 
able to detect specific CP metabolites using re­
cently developed gas chromatographic methods 
after the incubation of CP with S9 liver fractions 
instead of microsomes or purified cytochrome 
P450 (iso)enzymes (Sessink et a l, 1995a).
The biotransformation of CP was also studied 
in vivo by determination of unmetabolized CP in 
urine of rats pretreated with Aroclor 1254. CP 
was administered by intravenous injection. In 
addition, dermal application was chosen to 
mimic the possible dermal uptake as expected 
during occupational activities of hospital workers 
(Hirst et al., 1984; Sessink et al., 1994a).
»
2. Methods
2.1, Animal pretreatment fo r  the determination o f  
CP in urine
Four groups of three male random-bred Wis- 
tar rats (Cpb:WU (SPF), body wt about 215 g) 
were housed individually in stainless-steel metab­
olism cages and had free access to tap water and 
RMH food pellets (Hope Farms BV, Woerden, 
The Netherlands)* Urine samples and faeces were 
collected separately. Two groups of rats were 
pretreated with Aroclor 1254 (Alltech, Deerfield, 
IL, USA) in olive oil (i.p., 500 mg/kg body wt, 5 
days before CP administration) or olive oil as 
control (i.p., 2 ml/kg body wt). CP (ASTA- 
Medica, Frankfurt am Main, Germany) was ad­
ministered by dermal application or intravenous 
injection (penis vene) to a group of Aroclor 
1254-pretreated rats and to a group of control 
rats (1 mg/kg body wt). For dermal application, 
a glycerol suspension was applied on about 2
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cm2 of the closc-shavcn skin of the neck. Urine 
samples were collected, on ice water for 24,h.. A 
dose of 1 mg CP/kg body wt is about'^0000 
times higher when compared to the QcaipüHôrial 
exposure of hospital workers to CP >J( ïë ^ Î 8  /¿g
CP/day) (Sessink et al., 1995b).
4
2,2. Animal pretreatment for the in vitro incubations 
Six groups of three male and six groups of 
three female random-bred Wistar rats (Cpb:WU 
(SPF), body wt about 190 g) were used. The 
animals were housed per group. They had free 
access to tap water and RMH food pellets (Hope 
Farms BV, Woerden, The Netherlands). Groups 
of male and female rats were pretreated with 
Aroclor 1254 in olive oil (i.p., 500 mg/kg body wt, 
5 days before preparation of the S9 liver frac­
tion), phénobarbital (OPG, Utrecht, The Nether­
lands) in saline (i.p., male rats: 75 mg/kg body wt, 
female rats: 50 mg/kg body wt, during 4 days 
before preparation of the S9 liver fraction), ß- 
naphthoflavone (Janssen, Beerse, Belgium) in ol­
ive oil (i.p., 40 mg/kg body wt, during 3 days 
before preparation of the S9 liver fraction) and 
olive oil as control (i.p., 2 ml/kg body wt). 
Groups of ethanol-pretreated male and female 
rats were obtained by giving tap water contain­
ing 15% ethanol for 6 weeks. The corresponding 
control rats received tap water without ethanol 
(van de Wiel et al., 1990). The rats were anaesthe­
tized with pentobarbital and finally killed by 
cervical dislocation.
»
%
2 3  '. Preparation o f  the S9 liver fractions 
After cervical dislocation, the livers were per­
fused in situ with 0.9% NaCl (w/w), completely 
removed, weighed and immediately cooled in 
ice-cold SETH buffer (0.25 M sucrose, 2 mM 
EDTA and 10 mM Tris-HCl, pH 7.4). Liver 
homogenates were prepared (20%, w/v) in SETH 
buffer with a teflon-glass homogenizer. After cen­
trifugation at 9000 X g for 20 min, the floating fat 
layer was ’removed. The S9 liver fraction was 
divided in a number of samples, frozen in liquid 
N 2 and stored at -80°C  until use.
I 1 )
2.4. In vitro incubations 
The frozen S9 liver fractions were thawed 
quickly at 37°C immediately prior to use and
Kept;ou ice. The incubation mixture contained 44 
■ovfyl MOPS buffer pH 7.4, 2 mM N A D P, 5 mM 
•MgCl2 -6H 20 ,  2 mM glucose 6-phosphate, 1 
mM EDTA, 4 mM NAD, 5 mM GSH, and an 
amount of S9 liver fraction based on 0.35 nmol 
P450. After a preincubation of 5 min at 37°C, the 
incubation was started by adding 1.5 /¿moi CP. 
The final incubation volume was 1 ml. The mix­
ture was mildly shaken during the (pre)incuba- 
tion at 150 rev./min. The incubation was stopped 
after 30 min by the addition of 75 ¡A of a 6 M 
HC1 solution. The reaction mixture was immedi­
ately cooled on ice-water. All incubations were 
carried out double in triplicate. One series in 
triplicate was used for the determination of CAR 
and KCP. The other was used for the determina­
tion of NNM  (Sessink et a l, 1995a).
2.5. Enzyme measurements
Total cytochrome P450 was determined from 
the dilhionite-difference spectrum according to 
Rutten et al. (Rutten et al., 1987). Protein concen­
trations were measured by the Bradford method 
using crystalline bovine serum albumin as 
standard (Bradford, 1976). 7-Ethoxyresorufin-O- 
deethylase (EROD) and 7-pentoxyresorufin-O- 
deethylase (PROD) activities were determined 
according to Burke et al. and aniline-hydroxylase 
(AH) activity was measured according to Ishi- 
date et al. (Burke et al., 1985; Ishidate et al., 
1978). Enzyme and total cytochrome P450 mea­
surements were performed in duplicate. Protein 
concentrations were measured in triplicate.
2.6. Sample preparation and gas chromatographic 
analysis o f  CP in urine
After liquid-liquid extraction and derivatiz- 
ation with trifluoroacetic anhydride, CP was 
determined with gas chromatography/mass spec­
trometry (Sessink et al., 1991; 1992b).
2.7. Sample preparation and gas chromatographic 
analysis o f  the CP metabolites in the 
incubation mixture
After liquid-liquid extraction and derivatiz- 
ation, the metabolites are determined with gas 
chromatography and thermionic specific detec­
tion. NNM  was determined after derivatization
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with benzenesulphonyl chloride. KCP and CAR 
were determined after derivatization with N,N- 
dimethylformamide dimethyl acetal (Sessink et
al., 1995a).
3. Results
2.8. Statistical analysis 
Two-way analysis of variance (SAS procedure 
GLM) was used to study influence of pretreat­
ment and administration route for the in vivo 
experiments. These data were analyzed using 
Statistical Analysis System version 6.08 (SAS 
Institute Inc., Cary, NC, USA). Unpaired two- 
tailed T-tests were used to study influence of 
pretreatment, sex, and supplementation with 
N A D  and GSH for the in vitro incubations 
(Tables 2 and 3). Log-transformed data were 
used. InStat 1.1 was used as the software pack­
age. P values below 0.05 were considered to be 
significant.
3.1. Effect o f  Aroclor 1254 pretreatment and 
administration route on the urinary excretion o f  
unmetabolized CP  
CP was excreted in urine of control rats within 
16-20 h after intravenous and dermal adminis­
tration. After pretreatment with Aroclor 1254, 
CP excretion was completed at 4 -8  h after ad­
ministration. The cumulative CP excretion as 
percentage of the dose administered ( +  S.D.) 
was lower in the Aroclor 1254-pretreated rats 
(intravenous administration: 1.4 ±  0.4; dermal 
application: 0.6 ±  0.1) compared to the olive oil- 
pretreated control rats (intravenous administra­
tion: 7.6 ±  1,2; dermal application: 5.8 ±  1,1) 
(P <  0.0001). The cumulative CP excretion was 
also lower after dermal application (Aroclor 
1254-pretreated rats: 0.6 ±0 .1; olive oil control 
rats: 5.8 ±  1.1) compared to intravenous admin-
Table 1
Effect of pretreatment on total cytochrome P450 content, EROD, PROD and AH activities in rat S9 liver fractions1
Pretreatment Total P450 ERODb PRODc AHd
nmol/mg
protein
Fold6
increase
pmol/min/ 
mg protein
Foldc
increase
pmol/min/ 
mg protein
Fold*
increase
pmol/min/ 
mg protein
Fold6
increase
Male
Aroclor 1254 0.21 2.1 190 73 9.7 2.5 0.16 2.5
ß-Naphthoflavone 0.12 1.2 160 62 5.4 1.4 0.10 1.5
Olive oil control 0.10 lr 2.6 lf 3.8 lr 0.06 ir
Phénobarbitalf 0.24 2.4 29 5.3 15 4.5 0.12 2.5
Ethanol 0.16 1.5 4.5 0.8 3.5 1.0 0.14 2.9
Water control 0.10 lr 5.4 lr 3.3 lf 0.05 lr
Female •
Aroclor 1254 0.10 1.9 310 198 16 10 0.08 2.7
jö-Naphthoflavone 0.07 1.4 230 145 5.8 3.6 0.05 1.7
Olive oil control 0.05 lr 1.6 lr 1.6 lr 0.03 lr
Phénobarbital 0.06 0.6 2.8 0.9 8.1 6.5 0.03 0.6
Ethanol 0.18 1.9 2.6 0.8 1.4 1.1 0.13 2.5
Water control 0.10 lr 3.3 lf 1.3 lf 0.05 lf
aValues are means of pooled S9 fractions of 3 rats. 
bEROD, 7-ethoxyresorufìn-O-deethylase. 
cPROD, 7-pentoxyresorufin-O-deethylase. 
dAH, 4-aniline-hydroxylase.
'Induction was compared to olive and water control.
fFor both male and female rats, olive oil and water were set at 1.
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Table 2
Formation of NNM and CAR after incubation of CP with Aroclor 1254- and /?-naphthoflavone-pretreated rat S9 liver fractions3
Aroclor 1254
<S
Without supplementation with NAD and GSH
NNM 3300 ± 2000b*,c***
CAR 270 ± 110b*'c*
NNM + CAR 3600
NNM/CAR ratio 12.4
Supplementation with NAD
NNM 840 ± 510c***
CAR 1200 ± 480b*,c***,d*
NNM + CAR 2000
NNM/CAR ratio 0.70
Supplementation with NAD and GSH 
NNM 50 ±
CAR 780 ± 320b*,c**
NNM + CAR 830
NNM/CAR ratio 0.06
38 ± 23 
57 ± 23b* 
94 
0.66
14 4. 9b***
78 ± 32 
92 
0.18
Qc*#*
110 ± 44b* 
110
0
ß-Naphthofiavone Olive oil control
400 ± 240c** 
53 ± 22c* 
450 
7.6
80 + 48c****>d*
160 ± 64c***,d*
240
0.50
g 5c***,ç*
120 ± 48c* 
130 
0.06
?
17 ± 10 
14 + 6 
30 
1.2
Qd***
10 ± 4b* 
10 
0
0
26 i  
26 
0
11
570 ± 350e*** 
74 ± 30c*
640
7.7
180 ± 
330 ± 
520 
0.56
120e****
140c***,d*
14 4. Qc***,«:*
190 ± 77°** 
200 
0.07
?
8 ± 5 
19 ± 8 
27 
0.40
Qd***
36 ± 15 
36 
0
0
30 ± 
30 
0
13
“Values of NNM and CAR formation are means ± S.D. of 3 rats (pmol/min/mg protein). 
bSignificantly different from olive oil control pretreated male or female rats.
“Significant difference between male and female rats concerning the indicated pretreatment and (without) supplementation with 
NAD [and GSH).
dSignificant!y different from without supplementation with NAD and GSH concerning the indicated pretreatment and sex. 
'Significantly different from supplementation with NAD concerning the indicated pretreatment and sex.
*P< 0.05; **P < 0.01; ***P < 0.005; ****?< 0.0005,
istration (Aroclor 1254-pretreated rats: 1.4 ±  0.4; 
olive oil control rats: 7.6 ±  1.2) (P =  0.026). It is 
concluded that pretreatment with Aroclor 1254 
decreased the excretion of unmetabolized CP in 
urine of rats most likely due to an enhanced 
biotransformation of CP in vivo. The influence of 
the administration route was of minor import­
ance indicating almost complete dermal absorp­
tion.
3.2. Effect o f  pretreatment with cytochrome P450 
enzyme-inducers on enzyme activities 
As was expected, EROD activity was substan­
tially increased in both male and female rats after 
Aroclor 1254 pretreatment and to a lesser extent
-naphthoflavone pretreatment in compari­
son with the olive oil control rats (Table 1). 
EROD activity was slightly increased in male
rats after phénobarbital pretreatment. PROD ac­
tivity was slightly increased in male and female 
rats after phénobarbital and Aroclor 1254 pret­
reatment and in female rats after /?-naphtof- 
lavone pretreatment. AH activity was slightly 
enhanced in male and female rats after Aroclor 
1254 and ethanol pretreatment and in male rats 
after phénobarbital pretreatment.
3.3. Effect o f  pretreatment with cytochrome P450 
enzyme-inducers on the biotransformation o f  CP  
The rates of formation of N N M  and CAR after 
incubation of CP with S9 liver fractions pret­
reated and control male and female rats, and the 
influence of supplementation with N A D  and 
GSH are shown in Table 2 (Aroclor 1254, ß- 
naphthoflavone, and olive oil control) and Table 
3 (phénobarbital, ethanol, and water control). In
/
Table 3
Formation of NNM and CAR after incubation of CP with phénobarbital- and ethanol-pretreated rat S9 liver fractions3
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Phénobarbital Ethanol Water control
? 3 S S 9
Without supplementation with NAD and GSH
NNM 4700 ± 2800b*,c*** 57 ± 34 610 ± 370c*** 14 ± 9 390 ±  240c** 14 ± 9
CAR 390 ± Í60b*,c* 94 ± 38h* 60 ±  24 26 ± 11 94 ± 38c* 18 ± 8
NNM + CAR 5100 150 670 40 490 32
NNM/CAR ratio 11.9 0.61 10.2 0.54 4.2 0.74
Supplementation with NAD
NNM 2100 ± 1300b*,c*** 30 ± 18 260 ± 160c** 17 ± Î0 220 ± 140 60 ±  36
CAR 2400 ± 960b***‘c***>(1** 200 ± 82b*** 190 ± 76c*,d* 42 ± 17 300 ± 120c***,d* 20 + 9
NNM + CAR 4500 230 450 58 520 80
NNM/CAR ratio 0.88 0.15 1.4 0.40 0.74 3.0
Supplementation with NAD and GSH
NNM 57 ± 35c**-c*** 3 ± I 13*'** + 7c***,c** 0C*** 10 -H 7c**«e** QC*** *
CAR 1700 ± 670b***,c*** 250 ± 98b*** 150 ± 60c* 53 ± 22 210 ± 86c** 26 ± 12
NNM + CAR 1700 250 160 53 220 28
NNM/CAR ratio 0.03 0,01 0.08 0 0.05 0
aValues of NNM and CAR formation are means ±  S.D. of 3 rats (pmol/min/mg protein). 
bSignificantiy different from water control pretreated male or female rats,
Significant difference between male and female rats concerning the indicated pretreatment and (without) supplementation with 
NAD (and GSH).
dSignificantly different from without supplementation with NAD und GSH concerning the indicated pretreatment and sex. 
'Significantly different from supplementation with NAD concerning the indicated pretreatment and sex.
*P < 0.05; **/> < 0.01; ***P < 0.005; ****P < 0.0005.
none of the incubation mixtures K C P was detec­
ted ( <  0.5 nmol/ml incubation mixture). Conse­
quently, the formulas for the calculation of the 
total metabolite formation rate and the toxic/ 
non-toxic metabolites ratio are simplified in 
NNM  +  CAR and NNM /CAR, respectively.
3.4. Without supplementation with N A D  and GSH  
The results show that Aroclor 1254 and phéno­
barbital pretreatment increased the formation 
rate of N N M  in male rats and the formation rate 
of CAR in male and female rats compared to 
their corresponding controls. The formation rate 
of NNM  and CAR was not affected after /?- 
naphthoflavone and ethanol pretreatment. The 
formation rate of especially NNM  and to a lesser 
extent CAR is higher in male than in female rats
for all pretreatments and controls. Consequently, 
the total metabolite formation rate N N M  -f-CAR 
and the N N M /C A R  ratio is higher in male than 
in female rats.
3.5. Supplem entation with N A D
Supplementation of the S9 incubation mixtures 
with N A D  decreased the N N M  formation rate in 
/?-naphtoflavone-pretreated and in female olive 
oil-treated control rats. The N N M  formation 
rate was not affected by the other pretreatments 
and in the water control group. On the contrary, 
the CAR formation rate was increased in male 
rats for all pretreatments and their corresponding 
control groups more or less com pensating the 
decrease of the N N M  formation rate. Conse­
quently, the total m etabolite formation rate
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N N M  +  CAR was not changed and the N N M /  
CAR ratio was decreased (except for female 
water control rats).
In addition, Aroclor 1254 pretreatment in­
creased the formation rate of N N M  in female rats 
and the formation rate of CAR in male rats 
compared to their corresponding controls. The 
formation rate of CAR was decreased after ß - 
naphthoflavone pretreatment in female rats. 
Phénobarbital pretreatment increased the forma­
tion rate of N N M  in male rats and the formation 
rate of CAR in male and female rats compared to 
their corresponding controls. The formation rate 
of N N M  and CAR was not affected after ethanol 
pretreatment. The formation rate of N N M  and 
CAR is higher in male rats than in female rats for 
all pretreatments and the control groups (except 
the N N M  formation rate in the water control 
group).
3.6. Supplem entation with N A D  and G SH
Supplementation of the S9 incubation mixtures 
with N A D  and G SH  decreased the N N M  forma­
tion rate compared to N A D  supplementation 
alone. The CAR formation rate was not affected. 
Consequently, the N N M /C A R  ratio was de- 
creased. The total metabolite formation rate 
N N M  +  CAR was only decreased in the male 
rats. This is due to the large reduction in the 
N N M  formation rate in the male rats compared 
to the female rats. These results were not in­
fluenced by the pretreatment. Once again, the 
formation rate o f N N M  and CAR was higher in 
male rats than in female rats within each pre­
treatment.
In addition, Aroclor 1254 and phénobarbital 
pretreatment increased the formation rate of 
CAR compared to their corresponding controls. 
Phénobarbital pretreatment also increased the 
formation rate of N N M  in female rats.
4. Discussion
The cumulative urinary CP excretion (24 h) 
was significantly decreased in Aroclor 1254-pret­
reated rats when compared to control rats. An 
enhanced in vivo biotransformation of CP is
suggested and is confirmed by the results of the 
incubations in vitro which demonstrate an in­
crease in total CP metabolite formation after 
pretreatment with Aroclor 1254. These results 
suggest the influence of external (chemical) fac­
tors on CP biotransformation in vivo. The cumu­
lative CP excretion was lower after dermal 
application compared to intravenous administra­
tion. This suggests a higher biotransformation 
activity after dermal application than intra­
venous administration. Consequently more meta­
bolites could be formed after dermal application 
than after intravenous administration. However, 
it is unknown whether this will result in more 
toxic or non-toxic metabolites.
Several investigators have studied the in 
vitro hepatic biotransformation of CP in rats 
after pretreatment with phénobarbital, Aroclor 
1254, jS-naphtoflavone and 3-methylcholanthrene 
(Sladek, 1988; Clarke and Waxman, 1989; LeB- 
lanc and Waxman, 1989). The experiments were 
carried out with microsomes or purified cytoch­
rome P450 (iso)enzymes. The biotransformation 
of C P was measured by application of several 
methods. However, no data about specific CP 
metabolite formation were presented. It was 
shown that after phénobarbital pretreatment es­
pecially cytochrome P4502B1, contributed to the 
biotransformation of CP in the rat, whereas cyto­
chromes P4502C6 and 2C11 were responsible for 
the biotransformation of CP in control rat liver 
(Clarke and Waxman, 1989; LeBlanc and Wax­
man, 1989). Recently, it was demonstrated that 
CP hydroxylation in man was 
preferentially catalyzed by liver microsomal cyto­
chrome P4502B (Chang et al., 1993). It is sugges­
ted that induction of enzymes involved in CP 
biotransformation results in an increased thera­
peutic effect since more of the DNA-alkylating 
metabolite phosphoramide mustard is 
formed. However, the absence of NAD-linked  
aldehyde dehydrogenase and aldehyde oxidase in 
incubations with microsomes and purified P450 
systems might overestimate the formation of 
phosphoramide mustard because metabolites 
such as CAR and KCP could not be formed. It 
was our aim to study the effect of enzyme induc­
tion and sex on the formation of toxic (NNM )
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and non-toxic (CAR and KCP) CP metabolites 
in rat liver S9 fractions.
In common with other investigators, we also 
found that the biotransformation of CP was 
increased after Aroclor 1254 and phénobarbital 
pretreatment (Sladek, 1988; Clarke and Waxman, 
1989; LeBlanc and Waxman, 1989). However, the 
NNM /CAR ratio was slightly changed after 
Aroclor 1254 pretreatment but increased after 
phénobarbital pretreatment. This is possibly 
caused by a higher increase in CAR formation 
due to induction of aldehyde dehydrogenase 
(Lindahl, 1992).
The effects of smoking and alcohol on biotrans­
formation enzymes in the rat were mimicked by 
pretreatment of the rats with jS-naphthoflavone 
and ethanol, respectively. These so-called life­
style factors may cause induction or inhibition of 
enzymes involved in the biotransformation of 
toxic compounds such as CP (Fournier and 
Thomas, 1986). In the present study, no differen­
ces in the biotransformation of CP were observed 
after ß-naphthoflavone pretreatment (P4501A1 
induction) and after ethanol pretreatment 
(P4502E1 induction). From these results it could 
be concluded that pretreatment of rats with ß- 
naphthoflavone and ethanol did not increase CP 
hydroxylation. Comparable results were found in 
in vitro experiments with microsomes of human 
donor livers which showed that P4501A1, 1A2 
and 2E1 did not contribute to the hydroxylation 
of CP (Chang et al., 1993). In addition, we did 
not find a correlation between EROD activity 
and N N M , CAR, total metabolite formation and 
the N N M /C A R  ratio in a human liver incubation 
study (Sessink et al., 1995a). On the contrary, we 
found a correlation between CAR and total 
metabolite formation and AH activity while 
NNM  formation and the NNM /CAR ratio were 
not correlated.
The formation rate of NNM  and CAR will 
differ depending on the biological variation in 
NAD and GSH levels in rat and human liver. 
This variation, mimicked by supplementation 
with N A D  necessary for the formation of CAR, 
increased the formation of this metabolite and 
decreased the formation of N N M  as expected. In 
a corresponding way, N N M  formation was de­
creased after supplementation with GSH. This is 
explained by conjugation of the electrophiles 
NNM  and phosphoramide mustard.
We have found that the in vitro biotransforma­
tion of CP was strongly influenced by sex, and 
also by supplementation with NAD and GSH. It 
is concluded that pretreatment with the enzyme- 
inducers, ethanol and /?-naphtoflavone, did not 
influence the biotransformation of CP in the rat.
4
Hence, it is tempting to conclude that alcohol 
consumption and smoking, mimicked by pret­
reatment of rats with ethanol and /?-naphtho- 
flavone, respectively, will not affect CP biotrans­
formation in man.
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